Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

St James's Place rallies on robust H1 performance, redress provision release

(Sharecast News) - Wealth manager St James's Place traded higher on Thursday after the group published its interim report card, highlighting operational momentum and strategic progress across key initiatives. St James's Place said gross inflows rose 23% year-on-year to £10.5bn in the six months ended 30 June, while net inflows doubled to £3.8bn, supported by high client retention and positive investment performance.

Funds under management hit a record high of £198.5bn, up 4% from year-end, helping drive a 17% increase in its underlying cash result to £240.4m.

St James's Place also announced an £84.5m release from its Ongoing Service Evidence provision, following a revision to its redress methodology in line with updated FCA guidance. After tax, SJP said the £63.4m release will be returned to shareholders via a share buy-back, alongside a previously announced £32.1m interim repurchase.

The FTSE 100-listed firm also reaffirmed its ambition to double underlying cash between 2023 and 2030.

Chief executive Mark FitzPatrick: "I am pleased to report strong operating and financial performance in the first half of 2025. During the period our highly qualified, professional advisers helped over one million clients to navigate a complex macroeconomic environment, ensuring clients' financial plans remain on track for the future.

"The strategic progress we are making will strengthen our business for the future, ensuring we are best placed to continue to capitalise on the compelling market opportunity in UK wealth management. The demand and need for financial advice are high and here to stay."

As of 1000 BST, STJ shares were up 5.60% at 1,235p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.